Gilead Sciences (GILD) 'Crushed' the Quarter, Piper Jaffray Says; Remains Top Large-Cap Biotech Pick
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Gilead Sciences (GILD) Bullish Stance Reiterated at BMO Capital Amid 'Strong' Q1
May 1, 2015 7:00 AM EDTBMO Capital analyst Jim Birchenough reiterated an Outperform rating and $159 price target on Gilead Sciences (NASDAQ: GILD) following "strong" Q1 results after the close with room to expand in HCV.
Birchenough commented, "We are maintaining our Outperform rating on the shares of GILD... More
Gilead Sciences (GILD) Bullish Stance Reiterated at Baird on 'Beat and Raise' Q1
May 1, 2015 6:42 AM EDTBaird analyst Brian Skorney reiterated an Outperform rating and $126 price target on Gilead Sciences (NASDAQ: GILD) following 'beat and raise' Q1.
Skorney commented, "A sizeable beat should be enough to support the stock and perhaps stop the sector slide. We expect... More
Gilead Sciences (GILD) Tops Q1 EPS by 48c, Raises FY Revenue Guidance
April 30, 2015 4:02 PM EDTGilead Sciences (NASDAQ: GILD) reported Q1 EPS of $2.76, $0.48 better than the analyst estimate of $2.28. Revenue for the quarter came in at $7.59 billion versus the consensus estimate of $6.81 billion.
Gilead Sciences sees FY2015 revenue of $28-29 million, versus the consensus of $28.50... More
